<DOC>
	<DOCNO>NCT00484471</DOCNO>
	<brief_summary>To compare combination treatment aripiprazole plus valproate versus valproate alone prevention relapse bipolar I disorder patient symptomatic remission 5-6 week open-label acute treatment aripiprazole plus valproate manic mixed episode , without psychotic feature .</brief_summary>
	<brief_title>ABLE : Abilify Bipolar Disorder Long-term Effectiveness</brief_title>
	<detailed_description>Further study detail provide Korea OIAA</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>1 . Subjects able give inform consent , and/or consent obtain legally acceptable representative ( require IRB/IEC ) prior initiation protocol require procedure ; 2 . Subjects Bipolar I Disorder , manic mixed episode , without psychotic feature , define DSMIVTR confirm M.I.N.I . ; 3 . Subjects able understand nature study follow protocol requirement include prescribed dosage regimen , capsule/tablet ingestion , discontinuation prohibit concomitant medication , reliably rat assessment scale ; 4 . Subjects willing discontinue medication start signing inform consent study phase ( allow exception note Section 6.4.2 ) ; 5 . Men woman age ≥ 18 ≤ 65 year ; 6 . Subjects YMRS total score ≥ 20 ( assess prior entry openlabel acute treatment phase ) ; 7 . YMRS total score ≤ 12 2 consecutive visit ( assessed Week 5 and/or Week6 prior entry doubleblind treatment phase ) . 1 . WOCBP unwilling unable use acceptable method avoid pregnancy entire study period four week completion study . Acceptable method include oral , injectable implanted contraceptive , intrauterine device barrier method condom , diaphragm , spermicide ; 2 . Women pregnant breastfeeding ; 3 . Subjects present clinically current DSMIVTR diagnosis delirium , dementia , amnestic cognitive disorder , psychotic disorder ( e.g. , schizophrenia schizoaffective disorder ) . Also , subject borderline , paranoid , histrionic , schizotypal , schizoid , antisocial personality disorder ; 4 . Subjects current Axis I ( DSMIVTR ) diagnosis Bipolar II Disorder , rapid cyclers ( experience four manic depressive episode per year ) , Bipolar Disorder NOS , primary psychiatric disorder Bipolar I Disorder ; 5 . Subjects document evidence first manic episode ; 6 . Subjects consider treatment refractory manic symptom ; ( Note : subject fail ≥ 2 antimanic treatment , e.g. , antipsychotic , lithium , valproate carbamazepine therapeutic dose duration , exclusive current episode , obtain permission Otsuka medical monitor include subject ) 7 . Subjects previously nonresponsive aripiprazole manic symptom ; 8 . Subjects significant risk commit suicide base history , mental status exam , investigator 's judgment ; 9 . Subjects meet DSMIVTR criterion substance abuse within past three month , substance dependence* within past 6 month , include benzodiazepine ; ( * exceptional subject substance dependence nicotine caffeine ) ; 10 . Subjects thyroid pathology ( e.g. , hypothyroidism hyperthyroidism ) unless condition stabilize medication least past three month ; ( Note : Subjects abnormal thyroid function test may retested prior start study medication . Subjects abnormal thyroid function test screen eligible study , unless permission obtain Otsuka ) ; 11 . Subjects history evidence medical condition would expose undue risk significant adverse event interfere assessment safety efficacy course trial , include limited hepatic , renal , respiratory , cardiovascular , endocrine ( e.g. , Addison 's Disease ) , immune , neurologic , hematologic disease determine clinical judgment investigator ; 12 . Subjects significant history seizure disorder ( e.g. , epilepsy ) ; 13 . The following laboratory test result , vital sign , ECG find exclusionary : Platelets ≤ 75000/mm3 Hemoglobin ≤ 9g/dL Neutrophils , absolute ≤ 1000/ mm3 SGOT ( AST ) &gt; 3x Upper Limit Normal SGPT ( ALT ) &gt; 3x Upper Limit Normal Creatinine ≥ 2 mg/dL QTc &gt; 475 msec 14 . Subjects recent antipsychotic use CPK ≥ 550 IU ( Otsuka contact discus elevate CPK level ) ; 15 . Subjects know allergic , intolerant , unresponsive valproate aripiprazole ; 16 . Subjects history neuroleptic malignant syndrome antipsychotic agent ; 17 . Subjects likely require prohibit concomitant therapy study indicate Section 6.4 protocol ; 18 . Recent treatment recent manic mix acute episode long act antipsychotic last dose less one full cycle plus one week prior enter Phase 2 ( haloperidol decanoate treatment within past five week , fluphenazine decanoate treatment within past three week Risperdal ConstaTM treatment within past three week ) ; 19 . Subjects likely require initiation intensive individual psychotherapy course study ( Note : Group supportive therapy allow , part subject 's ongoing treatment . Individual psychotherapy allow subject consistently receive psychotherapy least 3 month prior study continue study ) ; 20 . ECT treatment within current episode within two month prior study ; 21 . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious disease ) illness must enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>